For the Kaplan–Meier analysis of OS, we observed that the evaluated TPD52L2 expression predicted worse OS of patients in 20 of 33 tumors in TCGA cohort, including ACC, BLCA, BRCA, COAD, GBM, HNSC, KIRC, KIRP, LAML, LGG, LIHC, LUAD, LUSC, MESO, OV, PAAD, PRAD, SKCM, THCA, and THYM (Figure 4). Here, TPD52L2 is linked to glioblastoma.